The relationship between blinatumomab exposure and efficacy endpoints (occurrence of complete remission [CR] and duration of overall survival [OS]) or adverse events (occurrence of cytokine release syndrome [CRS] and neurological events) were investigated in adult patients with relapsed/refractory acute lymphoblastic leukaemia (r/r ALL) receiving blinatumomab or standard of care (SOC) chemotherapy to evaluate appropriateness of the blinatumomab dosing regimen.
The objectives of the present analysis were to investigate the relationships between blinatumomab exposure and select efficacy (CR and OS) and safety (cytokine release syndrome [CRS] and neurological events [NEs] ) endpoints from patients diagnosed with Ph + or Ph-r/r ALL receiving blinatumomab or standard of care (SOC) chemotherapy in studies MT103-211 (blinatumomab alone), 10 20120216 (blinatumomab alone), 11 and 00103311 (blinatumomab or SOC). 12 An exposure-response (ER) analysis of blinatumomab reported for a phase 2 study (MT103-211 [NCT01466179]; n = 189) in r/r adult ALL 13 found an association of higher blinatumomab exposure with CR. However, this is the first ER analysis of blinatumomab including a larger adult r/r ALL patient population across 3 studies, including MT103-211, with a SOC arm for comparison. The appropriateness of the recommended blinatumomab regimen was evaluated based on the results of ER analyses to support justification of the tested dosing regimen for blinatumomab in treatment of r/r adult ALL. A statistically significant ER relationship for efficacy outcomes and no relationship for safety outcomes would indicate the optimal appropriateness.
2 | METHODS
| Clinical data
This ER analysis pooled data from 3 clinical studies (ClinicalTrials.gov, NCT01466179, NCT02000427, and NCT02013167) in 646 adult patients with ALL. Data from studies MT103-211, 10 20120216 11 and 00103311 12 were included in this analysis. In these 3 trials, patients received a cIV of blinatumomab at an initial dose of
What is already known about this subject
• Blinatumomab is approved to treat relapsed/refractory acute lymphoblastic leukaemia in adults and children
• Blinatumomab may cause cytokine release syndrome and neurological toxicities
• Blinatumomab increases median overall survival to 7.7 months vs 4.0 months with chemotherapy
What this study adds
• Increasing blinatumomab steady-state concentrations were associated with higher probabilities of achieving complete remission
• Increasing blinatumomab steady-state concentration was associated with longer durations of overall survival
• After accounting for blinatumomab treatment effect, magnitude of blinatumomab steady-state concentration was not associated with an increased probability of cytokine release syndrome or neurological events 9 μg/day for the 1 st week, followed by 28 μg/day for weeks 2-4 of the first cycle (C1 WK2) and for all subsequent 4-week cycles. There were 2-week blinatumomab-free periods between cycles. PK of blinatumomab were assessed in the first 2 treatment cycles for determination of blinatumomab concentration at steady state (C ss ) following 9 μg/day (week 1 of cycle 1: C1 WK1) and 28 μg/day cIV dosing for weeks 2-4 of cycle 1 or cycle 2. Patients randomized to receive SOC chemotherapy in the phase 3 study were assigned to one of the following chemotherapy regimens per the investigator's choice:
(i) fludarabine, cytarabine arabinoside and granulocyte colonystimulating factor; (ii) high-dose ara-C; (iii) high-dose methotrexatebased combination regimen; or (iv) clofarabine or clofarabine-based regimens. 14 Additional details of each clinical study used for the current analyses are reported elsewhere. [10] [11] [12] All studies were sponsored by Amgen Inc. and conducted in accordance with principles for human experimentation as defined in the Declaration of Helsinki and the International Conference on Harmonisation's Good Clinical Practice guidelines. The study protocols were approved by the respective institutional review boards. Informed consent was obtained from each patient after being told the potential risks and benefits, as well as the investigational nature of the study.
CR was defined as having ≤5% blasts in the bone marrow, no evidence of disease and full recovery of peripheral blood counts: platelets >100 000/μL, and absolute neutrophil count >1000/μL.
Occurrence of CR and duration of OS were efficacy endpoints in the studies, and hence selected as the efficacy endpoints in these analyses. NEs and CRS were previously identified as adverse events of interest. [10] [11] [12] 15 CRS was based on the reported terms, which were coded to the preferred term of 'cytokine release syndrome' or 'cytokine storm'. NEs were defined using a specific search strategy that included the Medical Dictionary for Regulatory Activities high-level group terms of cranial nerve disorders; 'deliria', including 'confusion'; 'disturbances in thinking and perception'; 'encephalopathies'; 'mental impairment disorders'; 'movement disorders', including 'Parkinsonism'; neurological disorders not elsewhere classified; neuromuscular disorders; personality disorders and disturbances in behaviour; psychiatric disorders not elsewhere classified; and seizures, including subtypes.
NEs of any grade were included.
| Sampling for blinatumomab C ss
Serum samples for determination of blinatumomab concentrations were collected at steady state following the 9 or 28 μg/day dose. In Study MT103-211, PK samples were taken during week 1 of cycle 1 (C1 WK1) following the 9 μg/day dose, and during weeks 2-4 of cycle 1 (C1 WK2) and cycle 2 following the 28 μg/day dose, with a median of 6 PK samples collected per patient. In Study 20120216, PK samples were collected during C1 WK1 following the 9 μg/day dose and during C1 WK2 and cycle 2 following the 28 μg/day dose, with a median of 2 PK samples collected per patient. In Study 00103311, PK samples were collected during C1 WK1 following the 9 μg/day dose and during week 3 of cycle 1 following the 28 μg/day dose in all patients who received blinatumomab, with a median of 2 PK samples collected per patient. Blinatumomab serum concentrations were assessed using a bioassay reported elsewhere. 16 This assay had a lower limit of quantitation of 50 pg/mL and % coefficient of variation of ≤20%.
| Software
Descriptive PK data analysis and ER analyses were performed using SAS version 9.4 on Microsoft Windows. Graphical and all other statistical analyses were performed with TIBCO Spotfire S+ version 8.0 or above (TIBCO Software Inc., Palo Alto, CA, USA) and R version 3.0.3.
| ER modelling
As an exploratory analysis, CR, duration of OS, occurrence of first CRS Occurrence analyses were conducted using univariate and multivariate logistic regression models, and the odds ratios (ORs) and respective 95% confidence intervals (95% CIs) were presented.
Time-to-event analyses were conducted using Cox proportional hazards models, and the hazard ratios (HRs) and respective 95% CIs are presented. Effects were considered significant in the univariate forward-selection analysis for P < .1 and in the multivariate analysis for P < .05. A significance level of .1 was selected to provide a conservative criterion, especially when assessing exposure-safety analysis, such that even if a covariate had a significance level of .1, it would not be dropped, and its effect further assessed during the multivariate analysis. P values were not adjusted for multiplicity of comparisons, and therefore, should be interpreted with caution.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 17 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18. Tables 1-3. A trend was seen where patients with Pro-B ALL had lower exposure, whereas women had slightly higher exposures. In the lowest quartile, there appeared to be higher blast counts (cycle 1), lower CD, and highest degree of bone marrow infiltration. Baseline CD19+ B cells could not be evaluated as a covariate in the analysis as it was only available in 32% of patients, all of whom were from Study MT103-211.
| Blinatumomab exposure and baseline covariates
A summary of mean (standard deviation) blinatumomab C ss by dose and treatment cycle is provided in Table 4 . Since blinatumomab at a given dose was constant over time during cIVs, individual C ss values were calculated as the average of observed serum concentrations collected during the infusion at each dose (Table 4 ). Individual levels of C ss in cycle 1 and cycle 2 for 28 μg/day were similar with the geometric mean of the individual ratios of cycle 2 exposure to cycle 1 exposure for those patients who had exposures in both cycles was 1.07, although the group mean/range in cycle 2 was greater than in cycle 1 due to survival bias because many patients with low exposure dropped out during cycle 1. The exploratory analyses shown in Tables pooled. Additionally, when evaluating effects in blinatumomab-treated patients alone, blinatumomab exposure was found to be significantly associated with CR (P < 0.05), suggesting the range of blinatumomab exposures following 28 μg/day was associated with a higher probability of CR. with a lower hazard of OS (P < 0.0001).
| Exposure-duration of OS analysis

| Exposure-CRS analysis
In the exposure-CRS analysis dataset, CRS events occurred in 76 No pharmacokinetic samples were collected in cycle 2 per study protocol.
In the univariate analyses for CRS events occurring in cycle 1 week 1, blinatumomab C ss was not associated with the probability of CRS during cycle 1 week 1. Following stepwise inclusion of covariate factors identified in the univariate analysis, the multivariate analyses for cycle 1 week 1, a higher CD3+ T-cell count was associated (OR [95% CI]: 1.018 [1.007-1.028]; P < .001) with a higher probability of CRS events, while higher body weight was no longer associated with probability of CRS events (P = .2031).
Thus, following administration of blinatumomab, a higher CD3+ Tcell count at baseline was associated with a higher occurrence of CRS events. Blinatumomab C ss was not associated with the occurrence of CRS events, suggesting that the variability in blinatumomab exposure following 9 or 28 μg/day dosing was not associated with the probability of a CRS event.
| Exposure-NEs analysis
In this exposure-safety analysis dataset, NEs (406) occurred in 353 (66%) of the 537 patients who received blinatumomab and in 53 FIGURE 1 Kaplan-Meier survival curve across exposure quartiles in patients treated with blinatumomab. CssCategory is the category based on quartiles of C ss . Black (CssCategory = 1), red (CssCategory = 2), blue (CssCategory = 3), and green (CssCategory = 4) lines represent, respectively, the overall survival KaplanMeier curves for the first (< 265.5 pg/mL), second (≥ 265.5 and < 501 pg/mL), third (≥ 501 and < 811.1 pg/mL) and fourth (≥ 811.1 pg/mL) exposure-based quartiles for patients treated with blinatumomab. C ss , steady-state concentration; OS, overall survival. Numbers indicate the number of subjects at risk at times matching the tick values for the x-axis ated with a higher probability of NEs (P < .05) after accounting for sex (female). To confirm the effect of blinatumomab C ss in patients receiving blinatumomab, the multivariate analyses of NEs occurring during cycle 1 week 1 or anytime during the study were updated to exclude the patients treated with SOC chemotherapy. Upon exclusion of these patients, blinatumomab exposure was not associated with the occurrence of NEs during cycle 1 week 1 (P = .3691) or anytime during the study (P = .1512).
Overall, blinatumomab treatment is associated with a higher probability of NEs compared to SOC chemotherapy treatment, and a higher blinatumomab C ss is not associated with a higher probability of NEs in blinatumomab-treated patients.
| DISCUSSION
Most blinatumomab clinical trials were single-arm studies. This is because of challenges in the enrolment of a significant number of patients with r/r ALL due to the rareness of disease and the unique approach to blinatumomab dosing (cIV infusion for a month), which prevents a double-blind study design to compare with SOC (mainly short IV infusion for some hours). This paper reports the first analysis combining valuable data from multiple studies of r/r ALL patients receiving SOC or blinatumomab. The ER relationship is one of the key determinants of the safety and effectiveness of drugs, and clinical benefit is determined by weighing the favourable and unfavourable effects at a particular dose. 18 However, some limitations of an ER analysis may include: (i) patients in the randomized clinical trials being balanced across treatment arms, and not necessarily across exposurebased groups; (ii) presence of unrecognized confounders, such the lack of sufficient baseline CD19+ B-cell data for evaluation as a covariate;
(iii) analysis of response for a specific endpoint at a given time point may not necessarily reflect the long-term effects of the drug. 19 Of note, a previous ER analysis demonstrated that lower proportions of CD19+ B cells at screening were significantly associated with achieving CR, a greater proportion in the occurrence of NEs, and shorter median time to NEs. 13 These limitations were considered during this ER analysis, and the results were interpreted after weighing in the Of the 646 patients included in the analysis dataset, 409 were not missing any of the covariates or C ss and were included in the multivariate analysis.
b Of the 646 patients included in the analysis dataset, 348 were not missing any of the covariates or C ss and were included in the multivariate analysis. Of the 646 patients included in the analysis dataset, 466 were not missing any of the covariates or C ss and were included in the multivariate analysis.
caveats in the analysis. However, given the lack of comparator arms in the 2 phase 2 studies included, other unknown confounding factors may have introduced an unidentified bias.
Blinatumomab PK was found to be stable with time (across cycles). Further, blinatumomab was given by cIV over the dosing interval, supporting the use of C ss at the relevant dose for the occurrence and time-to-event analyses. To adjust for potential confounding effects, covariates that were univariately significant were considered during multivariate analysis, and C ss was evaluated on top of significant baseline covariates, thus reducing the possibility of confounding effects on the ER relationship.
Exposure-efficacy analyses revealed a robust relationship multivariately between higher blinatumomab C ss and higher CR, both with and without SOC included. Higher Css was also associated with higher CR in a previous analysis using Study MT103-211 alone and this relationship persisted when Studies 20120216 and 00103311
were incorporated into the current 3-study analyses. tionship between the probability of CRS or NEs with the tested regimen was observed, after accounting for treatment effect. Thus, the blinatumomab step-dosing regimen was appropriate in the management of CRS and NEs.
In conclusion, the ER analysis indicated that blinatumomab exposure resulted in a greater probability of achieving CR and provided a longer OS than SOC chemotherapy. CRS occurred only during blinatumomab treatment, and the frequency of NEs was higher with blinatumomab treatment. Nevertheless, the recommended blinatumomab step-dosing regimen was appropriate in the management of CRS and NEs. In conclusion, the analysis demonstrates how ER analyses of phase 2 or 3 study data and their application can support the justification of an appropriate dosing regimen of a novel BiTE antibody construct, blinatumomab, in the treatment of adult r/r ALL.
